Hepatocellular carcinoma tumour burden score to stratify prognosis after resection
Background Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been largely adopted in clinical practice, recent studies have emphasized the need for further refinement and subclassification of this system. Methods Patients who underwent hepatectomy with curative intent for BCLC‐0,...
Gespeichert in:
| Veröffentlicht in: | British journal of surgery 2020-06, Vol.107 (7), p.854-864 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 864 |
|---|---|
| container_issue | 7 |
| container_start_page | 854 |
| container_title | British journal of surgery |
| container_volume | 107 |
| creator | Tsilimigras, D. I. Moris, D. Hyer, J. M. Bagante, F. Sahara, K. Moro, A. Paredes, A. Z. Mehta, R. Ratti, F. Marques, H. P. Silva, S. Soubrane, O. Lam, V. Poultsides, G. A. Popescu, I. Alexandrescu, S. Martel, G. Workneh, A. Guglielmi, A. Hugh, T. Aldrighetti, L. Endo, I. Sasaki, K. Rodarte, A. I. Aucejo, F. N. Pawlik, T. M. |
| description | Background
Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been largely adopted in clinical practice, recent studies have emphasized the need for further refinement and subclassification of this system.
Methods
Patients who underwent hepatectomy with curative intent for BCLC‐0, ‐A or ‐B hepatocellular carcinoma (HCC) between 2000 and 2017 were identified using a multi‐institutional database. The tumour burden score (TBS) was calculated, and overall survival (OS) was examined in relation to TBS and BCLC stage.
Results
Among 1053 patients, 63 (6·0 per cent) had BCLC‐0, 826 (78·4 per cent) BCLC‐A and 164 (15·6 per cent) had BCLC‐B HCC. OS worsened incrementally with higher TBS (5‐year OS 77·9, 61 and 39 per cent for low, medium and high TBS respectively; P < 0·001). No differences in OS were noted among patients with similar TBS, irrespective of BCLC stage (61·6 versus 58·9 per cent for BCLC‐A/medium TBS versus BCLC‐B/medium TBS, P = 0·930; 45 versus 13 per cent for BCLC‐A/high TBS versus BCLC‐B/high TBS, P = 0·175). Patients with BCLC‐B HCC and a medium TBS had better OS than those with BCLC‐A disease and a high TBS (58·9 versus 45 per cent; P = 0·005). On multivariable analysis, TBS remained associated with OS among patients with BCLC‐A (medium TBS: hazard ratio (HR) 2·07, 95 per cent c.i. 1·42 to 3·02, P < 0·001; high TBS: HR 4·05, 2·40 to 6·82, P < 0·001) and BCLC‐B (high TBS: HR 3·85, 2·03 to 7·30; P < 0·001) HCC. TBS could also stratify prognosis among patients in an external validation cohort (5‐year OS 79, 51·2 and 28 per cent for low, medium and high TBS respectively; P = 0·010).
Conclusion
The prognosis of patients with HCC varied according to the BCLC stage but was largely dependent on the TBS.
Antecedentes
Aunque el sistema de estadificación del Barcelona Clinic Liver Cancer (BCLC) ha sido adoptado en gran medida en la práctica clínica, estudios recientes han enfatizado la necesidad de un mayor refinamiento y subclasificación del sistema BCLC.
Métodos
Los pacientes con carcinoma hepatocelular (hepatocellular cancer, HCC) BCLC‐0, A y B que se sometieron a una hepatectomía con intención curativa entre 2000 y 2017 fueron identificados utilizando una base de datos multi‐institucional. Se calculó la puntuación de carga tumoral (tumour burden score, TBS) y se examinó la supervivencia global (overall survival, OS) en relación con la TBS y los estadios BCLC.
Resultados
En la serie de 1.053 pacientes, 63 (6%) tenían HCC BCLC‐0, 826 (78 |
| doi_str_mv | 10.1002/bjs.11464 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2355946644</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2355946644</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3824-237ab97076adf23bfb8af13f0d784ef2cb89eb129299d9e0d7367ba0c64174f83</originalsourceid><addsrcrecordid>eNpdkctOwzAQRS0EoqWw4AeQJTZs0voVO1lCBRRUCYnH2rITG6VK4mI7Qv173AcsWM1o5mg0914ALjGaYoTITK_CFGPG2REYY8rzjGBeHIMxQkhkmBI6AmchrBDCFOXkFIwoQbnAKB-D14VZq-gq07ZDqzyslK-a3nUKxqFzg4d68LXpYaicNzA6GKJXsbEbuPbus3ehCVDZaDz0JpgqNq4_BydWtcFcHOoEfDzcv88X2fLl8Wl-u8wqWhCWESqULgUSXNWWUG11oSymFtWiYMaSShel0ZiUpCzr0qQx5UIrVHGGBbMFnYCb_d30yddgQpRdE7ZCVG_cECSheV4yzhlL6PU_dJW09ek7SRgSJHnBt9TVgRp0Z2q59k2n_Eb-upWA2R74blqz-dtjJLcxyBSD3MUg757fdg39AQBCedk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2407271064</pqid></control><display><type>article</type><title>Hepatocellular carcinoma tumour burden score to stratify prognosis after resection</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Tsilimigras, D. I. ; Moris, D. ; Hyer, J. M. ; Bagante, F. ; Sahara, K. ; Moro, A. ; Paredes, A. Z. ; Mehta, R. ; Ratti, F. ; Marques, H. P. ; Silva, S. ; Soubrane, O. ; Lam, V. ; Poultsides, G. A. ; Popescu, I. ; Alexandrescu, S. ; Martel, G. ; Workneh, A. ; Guglielmi, A. ; Hugh, T. ; Aldrighetti, L. ; Endo, I. ; Sasaki, K. ; Rodarte, A. I. ; Aucejo, F. N. ; Pawlik, T. M.</creator><creatorcontrib>Tsilimigras, D. I. ; Moris, D. ; Hyer, J. M. ; Bagante, F. ; Sahara, K. ; Moro, A. ; Paredes, A. Z. ; Mehta, R. ; Ratti, F. ; Marques, H. P. ; Silva, S. ; Soubrane, O. ; Lam, V. ; Poultsides, G. A. ; Popescu, I. ; Alexandrescu, S. ; Martel, G. ; Workneh, A. ; Guglielmi, A. ; Hugh, T. ; Aldrighetti, L. ; Endo, I. ; Sasaki, K. ; Rodarte, A. I. ; Aucejo, F. N. ; Pawlik, T. M.</creatorcontrib><description><![CDATA[Background
Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been largely adopted in clinical practice, recent studies have emphasized the need for further refinement and subclassification of this system.
Methods
Patients who underwent hepatectomy with curative intent for BCLC‐0, ‐A or ‐B hepatocellular carcinoma (HCC) between 2000 and 2017 were identified using a multi‐institutional database. The tumour burden score (TBS) was calculated, and overall survival (OS) was examined in relation to TBS and BCLC stage.
Results
Among 1053 patients, 63 (6·0 per cent) had BCLC‐0, 826 (78·4 per cent) BCLC‐A and 164 (15·6 per cent) had BCLC‐B HCC. OS worsened incrementally with higher TBS (5‐year OS 77·9, 61 and 39 per cent for low, medium and high TBS respectively; P < 0·001). No differences in OS were noted among patients with similar TBS, irrespective of BCLC stage (61·6 versus 58·9 per cent for BCLC‐A/medium TBS versus BCLC‐B/medium TBS, P = 0·930; 45 versus 13 per cent for BCLC‐A/high TBS versus BCLC‐B/high TBS, P = 0·175). Patients with BCLC‐B HCC and a medium TBS had better OS than those with BCLC‐A disease and a high TBS (58·9 versus 45 per cent; P = 0·005). On multivariable analysis, TBS remained associated with OS among patients with BCLC‐A (medium TBS: hazard ratio (HR) 2·07, 95 per cent c.i. 1·42 to 3·02, P < 0·001; high TBS: HR 4·05, 2·40 to 6·82, P < 0·001) and BCLC‐B (high TBS: HR 3·85, 2·03 to 7·30; P < 0·001) HCC. TBS could also stratify prognosis among patients in an external validation cohort (5‐year OS 79, 51·2 and 28 per cent for low, medium and high TBS respectively; P = 0·010).
Conclusion
The prognosis of patients with HCC varied according to the BCLC stage but was largely dependent on the TBS.
Antecedentes
Aunque el sistema de estadificación del Barcelona Clinic Liver Cancer (BCLC) ha sido adoptado en gran medida en la práctica clínica, estudios recientes han enfatizado la necesidad de un mayor refinamiento y subclasificación del sistema BCLC.
Métodos
Los pacientes con carcinoma hepatocelular (hepatocellular cancer, HCC) BCLC‐0, A y B que se sometieron a una hepatectomía con intención curativa entre 2000 y 2017 fueron identificados utilizando una base de datos multi‐institucional. Se calculó la puntuación de carga tumoral (tumour burden score, TBS) y se examinó la supervivencia global (overall survival, OS) en relación con la TBS y los estadios BCLC.
Resultados
En la serie de 1.053 pacientes, 63 (6%) tenían HCC BCLC‐0, 826 (78,4%) HCC BCLC‐A y 164 (15,6%) HCC BCLC‐B. La OS disminuyó de forma incremental en función de la mayor TBS (OS a 5 años; TBS baja: 77,9% versus TBS media: 61% versus TBS alta: 39%, P < 0,001). No se observaron diferencias en la OS entre pacientes con una puntuación TBS similar, independientemente del estadio BCLC (BCLC‐A/TBS media: 61,6% versus BCLC‐B/TBS media: 58,9%, P = 0,93; BCLC‐A/TBS alta: 45,1% versus BCLC‐B/TBS alta: 12,8%, P = 0,175). Los pacientes con BCLC‐B/TBS media tuvieron una mejor OS que los pacientes con BCLC‐A/TBS alta (58,9% versus 45,1%, P = 0,005). En el análisis multivariable, la TBS se mantuvo asociada a la OS en el caso de BCLC‐A (TBS media: cociente de riesgos instantáneos, hazard ratio, HR = 2,07, i.c. del 95%: 1,42‐3,02, P < 0,001; TBS alta: HR = 4,05, i.c. del 95%: 2,40‐6,82, P < 0,001) y BCLC‐B pacientes (TBS alta: HR = 3,85, i.c. del 95%: 2,03‐7,30, P < 0,001). La TBS también pudo estratificar el pronóstico entre pacientes en una cohorte de validación externa (OS a 5 años; TBS baja: 78,7% versus TBS media: 51,2% versus TBS alta: 27,6%, P = 0,01).
Conclusión
El pronóstico de los pacientes con HCC varió según el estadio BCLC, pero dependió en gran medida de la TBS.
The prognosis of patients with hepatocellular carcinoma varied according to the Barcelona Clinic Liver Cancer (BCLC) stage; yet, it was largely dependent on the tumour burden score (TBS). Following resection, patients with similar TBS had comparable long‐term outcomes, regardless of BCLC status, suggesting the need for further subclassification of the current BCLC guidelines and refinement of the proposed treatment algorithm using an assessment of total tumour burden.
Added value]]></description><identifier>ISSN: 0007-1323</identifier><identifier>EISSN: 1365-2168</identifier><identifier>DOI: 10.1002/bjs.11464</identifier><identifier>PMID: 32057105</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Aged ; Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - surgery ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Liver cancer ; Liver Neoplasms - diagnosis ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - surgery ; Male ; Medical prognosis ; Middle Aged ; Neoplasm Staging - methods ; Prognosis ; Survival Analysis ; Tumor Burden</subject><ispartof>British journal of surgery, 2020-06, Vol.107 (7), p.854-864</ispartof><rights>2020 BJS Society Ltd Published by John Wiley & Sons Ltd</rights><rights>2020 BJS Society Ltd Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2020 BJS Society Ltd. Published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3824-237ab97076adf23bfb8af13f0d784ef2cb89eb129299d9e0d7367ba0c64174f83</citedby><orcidid>0000-0002-7994-9870 ; 0000-0002-5386-0958 ; 0000-0002-3676-9263 ; 0000-0001-7729-2468</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fbjs.11464$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbjs.11464$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32057105$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsilimigras, D. I.</creatorcontrib><creatorcontrib>Moris, D.</creatorcontrib><creatorcontrib>Hyer, J. M.</creatorcontrib><creatorcontrib>Bagante, F.</creatorcontrib><creatorcontrib>Sahara, K.</creatorcontrib><creatorcontrib>Moro, A.</creatorcontrib><creatorcontrib>Paredes, A. Z.</creatorcontrib><creatorcontrib>Mehta, R.</creatorcontrib><creatorcontrib>Ratti, F.</creatorcontrib><creatorcontrib>Marques, H. P.</creatorcontrib><creatorcontrib>Silva, S.</creatorcontrib><creatorcontrib>Soubrane, O.</creatorcontrib><creatorcontrib>Lam, V.</creatorcontrib><creatorcontrib>Poultsides, G. A.</creatorcontrib><creatorcontrib>Popescu, I.</creatorcontrib><creatorcontrib>Alexandrescu, S.</creatorcontrib><creatorcontrib>Martel, G.</creatorcontrib><creatorcontrib>Workneh, A.</creatorcontrib><creatorcontrib>Guglielmi, A.</creatorcontrib><creatorcontrib>Hugh, T.</creatorcontrib><creatorcontrib>Aldrighetti, L.</creatorcontrib><creatorcontrib>Endo, I.</creatorcontrib><creatorcontrib>Sasaki, K.</creatorcontrib><creatorcontrib>Rodarte, A. I.</creatorcontrib><creatorcontrib>Aucejo, F. N.</creatorcontrib><creatorcontrib>Pawlik, T. M.</creatorcontrib><title>Hepatocellular carcinoma tumour burden score to stratify prognosis after resection</title><title>British journal of surgery</title><addtitle>Br J Surg</addtitle><description><![CDATA[Background
Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been largely adopted in clinical practice, recent studies have emphasized the need for further refinement and subclassification of this system.
Methods
Patients who underwent hepatectomy with curative intent for BCLC‐0, ‐A or ‐B hepatocellular carcinoma (HCC) between 2000 and 2017 were identified using a multi‐institutional database. The tumour burden score (TBS) was calculated, and overall survival (OS) was examined in relation to TBS and BCLC stage.
Results
Among 1053 patients, 63 (6·0 per cent) had BCLC‐0, 826 (78·4 per cent) BCLC‐A and 164 (15·6 per cent) had BCLC‐B HCC. OS worsened incrementally with higher TBS (5‐year OS 77·9, 61 and 39 per cent for low, medium and high TBS respectively; P < 0·001). No differences in OS were noted among patients with similar TBS, irrespective of BCLC stage (61·6 versus 58·9 per cent for BCLC‐A/medium TBS versus BCLC‐B/medium TBS, P = 0·930; 45 versus 13 per cent for BCLC‐A/high TBS versus BCLC‐B/high TBS, P = 0·175). Patients with BCLC‐B HCC and a medium TBS had better OS than those with BCLC‐A disease and a high TBS (58·9 versus 45 per cent; P = 0·005). On multivariable analysis, TBS remained associated with OS among patients with BCLC‐A (medium TBS: hazard ratio (HR) 2·07, 95 per cent c.i. 1·42 to 3·02, P < 0·001; high TBS: HR 4·05, 2·40 to 6·82, P < 0·001) and BCLC‐B (high TBS: HR 3·85, 2·03 to 7·30; P < 0·001) HCC. TBS could also stratify prognosis among patients in an external validation cohort (5‐year OS 79, 51·2 and 28 per cent for low, medium and high TBS respectively; P = 0·010).
Conclusion
The prognosis of patients with HCC varied according to the BCLC stage but was largely dependent on the TBS.
Antecedentes
Aunque el sistema de estadificación del Barcelona Clinic Liver Cancer (BCLC) ha sido adoptado en gran medida en la práctica clínica, estudios recientes han enfatizado la necesidad de un mayor refinamiento y subclasificación del sistema BCLC.
Métodos
Los pacientes con carcinoma hepatocelular (hepatocellular cancer, HCC) BCLC‐0, A y B que se sometieron a una hepatectomía con intención curativa entre 2000 y 2017 fueron identificados utilizando una base de datos multi‐institucional. Se calculó la puntuación de carga tumoral (tumour burden score, TBS) y se examinó la supervivencia global (overall survival, OS) en relación con la TBS y los estadios BCLC.
Resultados
En la serie de 1.053 pacientes, 63 (6%) tenían HCC BCLC‐0, 826 (78,4%) HCC BCLC‐A y 164 (15,6%) HCC BCLC‐B. La OS disminuyó de forma incremental en función de la mayor TBS (OS a 5 años; TBS baja: 77,9% versus TBS media: 61% versus TBS alta: 39%, P < 0,001). No se observaron diferencias en la OS entre pacientes con una puntuación TBS similar, independientemente del estadio BCLC (BCLC‐A/TBS media: 61,6% versus BCLC‐B/TBS media: 58,9%, P = 0,93; BCLC‐A/TBS alta: 45,1% versus BCLC‐B/TBS alta: 12,8%, P = 0,175). Los pacientes con BCLC‐B/TBS media tuvieron una mejor OS que los pacientes con BCLC‐A/TBS alta (58,9% versus 45,1%, P = 0,005). En el análisis multivariable, la TBS se mantuvo asociada a la OS en el caso de BCLC‐A (TBS media: cociente de riesgos instantáneos, hazard ratio, HR = 2,07, i.c. del 95%: 1,42‐3,02, P < 0,001; TBS alta: HR = 4,05, i.c. del 95%: 2,40‐6,82, P < 0,001) y BCLC‐B pacientes (TBS alta: HR = 3,85, i.c. del 95%: 2,03‐7,30, P < 0,001). La TBS también pudo estratificar el pronóstico entre pacientes en una cohorte de validación externa (OS a 5 años; TBS baja: 78,7% versus TBS media: 51,2% versus TBS alta: 27,6%, P = 0,01).
Conclusión
El pronóstico de los pacientes con HCC varió según el estadio BCLC, pero dependió en gran medida de la TBS.
The prognosis of patients with hepatocellular carcinoma varied according to the Barcelona Clinic Liver Cancer (BCLC) stage; yet, it was largely dependent on the tumour burden score (TBS). Following resection, patients with similar TBS had comparable long‐term outcomes, regardless of BCLC status, suggesting the need for further subclassification of the current BCLC guidelines and refinement of the proposed treatment algorithm using an assessment of total tumour burden.
Added value]]></description><subject>Aged</subject><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Neoplasm Staging - methods</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><subject>Tumor Burden</subject><issn>0007-1323</issn><issn>1365-2168</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctOwzAQRS0EoqWw4AeQJTZs0voVO1lCBRRUCYnH2rITG6VK4mI7Qv173AcsWM1o5mg0914ALjGaYoTITK_CFGPG2REYY8rzjGBeHIMxQkhkmBI6AmchrBDCFOXkFIwoQbnAKB-D14VZq-gq07ZDqzyslK-a3nUKxqFzg4d68LXpYaicNzA6GKJXsbEbuPbus3ehCVDZaDz0JpgqNq4_BydWtcFcHOoEfDzcv88X2fLl8Wl-u8wqWhCWESqULgUSXNWWUG11oSymFtWiYMaSShel0ZiUpCzr0qQx5UIrVHGGBbMFnYCb_d30yddgQpRdE7ZCVG_cECSheV4yzhlL6PU_dJW09ek7SRgSJHnBt9TVgRp0Z2q59k2n_Eb-upWA2R74blqz-dtjJLcxyBSD3MUg757fdg39AQBCedk</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Tsilimigras, D. I.</creator><creator>Moris, D.</creator><creator>Hyer, J. M.</creator><creator>Bagante, F.</creator><creator>Sahara, K.</creator><creator>Moro, A.</creator><creator>Paredes, A. Z.</creator><creator>Mehta, R.</creator><creator>Ratti, F.</creator><creator>Marques, H. P.</creator><creator>Silva, S.</creator><creator>Soubrane, O.</creator><creator>Lam, V.</creator><creator>Poultsides, G. A.</creator><creator>Popescu, I.</creator><creator>Alexandrescu, S.</creator><creator>Martel, G.</creator><creator>Workneh, A.</creator><creator>Guglielmi, A.</creator><creator>Hugh, T.</creator><creator>Aldrighetti, L.</creator><creator>Endo, I.</creator><creator>Sasaki, K.</creator><creator>Rodarte, A. I.</creator><creator>Aucejo, F. N.</creator><creator>Pawlik, T. M.</creator><general>John Wiley & Sons, Ltd</general><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7994-9870</orcidid><orcidid>https://orcid.org/0000-0002-5386-0958</orcidid><orcidid>https://orcid.org/0000-0002-3676-9263</orcidid><orcidid>https://orcid.org/0000-0001-7729-2468</orcidid></search><sort><creationdate>202006</creationdate><title>Hepatocellular carcinoma tumour burden score to stratify prognosis after resection</title><author>Tsilimigras, D. I. ; Moris, D. ; Hyer, J. M. ; Bagante, F. ; Sahara, K. ; Moro, A. ; Paredes, A. Z. ; Mehta, R. ; Ratti, F. ; Marques, H. P. ; Silva, S. ; Soubrane, O. ; Lam, V. ; Poultsides, G. A. ; Popescu, I. ; Alexandrescu, S. ; Martel, G. ; Workneh, A. ; Guglielmi, A. ; Hugh, T. ; Aldrighetti, L. ; Endo, I. ; Sasaki, K. ; Rodarte, A. I. ; Aucejo, F. N. ; Pawlik, T. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3824-237ab97076adf23bfb8af13f0d784ef2cb89eb129299d9e0d7367ba0c64174f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Neoplasm Staging - methods</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsilimigras, D. I.</creatorcontrib><creatorcontrib>Moris, D.</creatorcontrib><creatorcontrib>Hyer, J. M.</creatorcontrib><creatorcontrib>Bagante, F.</creatorcontrib><creatorcontrib>Sahara, K.</creatorcontrib><creatorcontrib>Moro, A.</creatorcontrib><creatorcontrib>Paredes, A. Z.</creatorcontrib><creatorcontrib>Mehta, R.</creatorcontrib><creatorcontrib>Ratti, F.</creatorcontrib><creatorcontrib>Marques, H. P.</creatorcontrib><creatorcontrib>Silva, S.</creatorcontrib><creatorcontrib>Soubrane, O.</creatorcontrib><creatorcontrib>Lam, V.</creatorcontrib><creatorcontrib>Poultsides, G. A.</creatorcontrib><creatorcontrib>Popescu, I.</creatorcontrib><creatorcontrib>Alexandrescu, S.</creatorcontrib><creatorcontrib>Martel, G.</creatorcontrib><creatorcontrib>Workneh, A.</creatorcontrib><creatorcontrib>Guglielmi, A.</creatorcontrib><creatorcontrib>Hugh, T.</creatorcontrib><creatorcontrib>Aldrighetti, L.</creatorcontrib><creatorcontrib>Endo, I.</creatorcontrib><creatorcontrib>Sasaki, K.</creatorcontrib><creatorcontrib>Rodarte, A. I.</creatorcontrib><creatorcontrib>Aucejo, F. N.</creatorcontrib><creatorcontrib>Pawlik, T. M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsilimigras, D. I.</au><au>Moris, D.</au><au>Hyer, J. M.</au><au>Bagante, F.</au><au>Sahara, K.</au><au>Moro, A.</au><au>Paredes, A. Z.</au><au>Mehta, R.</au><au>Ratti, F.</au><au>Marques, H. P.</au><au>Silva, S.</au><au>Soubrane, O.</au><au>Lam, V.</au><au>Poultsides, G. A.</au><au>Popescu, I.</au><au>Alexandrescu, S.</au><au>Martel, G.</au><au>Workneh, A.</au><au>Guglielmi, A.</au><au>Hugh, T.</au><au>Aldrighetti, L.</au><au>Endo, I.</au><au>Sasaki, K.</au><au>Rodarte, A. I.</au><au>Aucejo, F. N.</au><au>Pawlik, T. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatocellular carcinoma tumour burden score to stratify prognosis after resection</atitle><jtitle>British journal of surgery</jtitle><addtitle>Br J Surg</addtitle><date>2020-06</date><risdate>2020</risdate><volume>107</volume><issue>7</issue><spage>854</spage><epage>864</epage><pages>854-864</pages><issn>0007-1323</issn><eissn>1365-2168</eissn><abstract><![CDATA[Background
Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been largely adopted in clinical practice, recent studies have emphasized the need for further refinement and subclassification of this system.
Methods
Patients who underwent hepatectomy with curative intent for BCLC‐0, ‐A or ‐B hepatocellular carcinoma (HCC) between 2000 and 2017 were identified using a multi‐institutional database. The tumour burden score (TBS) was calculated, and overall survival (OS) was examined in relation to TBS and BCLC stage.
Results
Among 1053 patients, 63 (6·0 per cent) had BCLC‐0, 826 (78·4 per cent) BCLC‐A and 164 (15·6 per cent) had BCLC‐B HCC. OS worsened incrementally with higher TBS (5‐year OS 77·9, 61 and 39 per cent for low, medium and high TBS respectively; P < 0·001). No differences in OS were noted among patients with similar TBS, irrespective of BCLC stage (61·6 versus 58·9 per cent for BCLC‐A/medium TBS versus BCLC‐B/medium TBS, P = 0·930; 45 versus 13 per cent for BCLC‐A/high TBS versus BCLC‐B/high TBS, P = 0·175). Patients with BCLC‐B HCC and a medium TBS had better OS than those with BCLC‐A disease and a high TBS (58·9 versus 45 per cent; P = 0·005). On multivariable analysis, TBS remained associated with OS among patients with BCLC‐A (medium TBS: hazard ratio (HR) 2·07, 95 per cent c.i. 1·42 to 3·02, P < 0·001; high TBS: HR 4·05, 2·40 to 6·82, P < 0·001) and BCLC‐B (high TBS: HR 3·85, 2·03 to 7·30; P < 0·001) HCC. TBS could also stratify prognosis among patients in an external validation cohort (5‐year OS 79, 51·2 and 28 per cent for low, medium and high TBS respectively; P = 0·010).
Conclusion
The prognosis of patients with HCC varied according to the BCLC stage but was largely dependent on the TBS.
Antecedentes
Aunque el sistema de estadificación del Barcelona Clinic Liver Cancer (BCLC) ha sido adoptado en gran medida en la práctica clínica, estudios recientes han enfatizado la necesidad de un mayor refinamiento y subclasificación del sistema BCLC.
Métodos
Los pacientes con carcinoma hepatocelular (hepatocellular cancer, HCC) BCLC‐0, A y B que se sometieron a una hepatectomía con intención curativa entre 2000 y 2017 fueron identificados utilizando una base de datos multi‐institucional. Se calculó la puntuación de carga tumoral (tumour burden score, TBS) y se examinó la supervivencia global (overall survival, OS) en relación con la TBS y los estadios BCLC.
Resultados
En la serie de 1.053 pacientes, 63 (6%) tenían HCC BCLC‐0, 826 (78,4%) HCC BCLC‐A y 164 (15,6%) HCC BCLC‐B. La OS disminuyó de forma incremental en función de la mayor TBS (OS a 5 años; TBS baja: 77,9% versus TBS media: 61% versus TBS alta: 39%, P < 0,001). No se observaron diferencias en la OS entre pacientes con una puntuación TBS similar, independientemente del estadio BCLC (BCLC‐A/TBS media: 61,6% versus BCLC‐B/TBS media: 58,9%, P = 0,93; BCLC‐A/TBS alta: 45,1% versus BCLC‐B/TBS alta: 12,8%, P = 0,175). Los pacientes con BCLC‐B/TBS media tuvieron una mejor OS que los pacientes con BCLC‐A/TBS alta (58,9% versus 45,1%, P = 0,005). En el análisis multivariable, la TBS se mantuvo asociada a la OS en el caso de BCLC‐A (TBS media: cociente de riesgos instantáneos, hazard ratio, HR = 2,07, i.c. del 95%: 1,42‐3,02, P < 0,001; TBS alta: HR = 4,05, i.c. del 95%: 2,40‐6,82, P < 0,001) y BCLC‐B pacientes (TBS alta: HR = 3,85, i.c. del 95%: 2,03‐7,30, P < 0,001). La TBS también pudo estratificar el pronóstico entre pacientes en una cohorte de validación externa (OS a 5 años; TBS baja: 78,7% versus TBS media: 51,2% versus TBS alta: 27,6%, P = 0,01).
Conclusión
El pronóstico de los pacientes con HCC varió según el estadio BCLC, pero dependió en gran medida de la TBS.
The prognosis of patients with hepatocellular carcinoma varied according to the Barcelona Clinic Liver Cancer (BCLC) stage; yet, it was largely dependent on the tumour burden score (TBS). Following resection, patients with similar TBS had comparable long‐term outcomes, regardless of BCLC status, suggesting the need for further subclassification of the current BCLC guidelines and refinement of the proposed treatment algorithm using an assessment of total tumour burden.
Added value]]></abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>32057105</pmid><doi>10.1002/bjs.11464</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-7994-9870</orcidid><orcidid>https://orcid.org/0000-0002-5386-0958</orcidid><orcidid>https://orcid.org/0000-0002-3676-9263</orcidid><orcidid>https://orcid.org/0000-0001-7729-2468</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1323 |
| ispartof | British journal of surgery, 2020-06, Vol.107 (7), p.854-864 |
| issn | 0007-1323 1365-2168 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2355946644 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Aged Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Disease-Free Survival Female Humans Kaplan-Meier Estimate Liver cancer Liver Neoplasms - diagnosis Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - surgery Male Medical prognosis Middle Aged Neoplasm Staging - methods Prognosis Survival Analysis Tumor Burden |
| title | Hepatocellular carcinoma tumour burden score to stratify prognosis after resection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T03%3A38%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatocellular%20carcinoma%20tumour%20burden%20score%20to%20stratify%20prognosis%20after%20resection&rft.jtitle=British%20journal%20of%20surgery&rft.au=Tsilimigras,%20D.%20I.&rft.date=2020-06&rft.volume=107&rft.issue=7&rft.spage=854&rft.epage=864&rft.pages=854-864&rft.issn=0007-1323&rft.eissn=1365-2168&rft_id=info:doi/10.1002/bjs.11464&rft_dat=%3Cproquest_pubme%3E2355946644%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2407271064&rft_id=info:pmid/32057105&rfr_iscdi=true |